Rising Awareness about Depression and Related Treatment are Expected to Drive the Selective Serotonin Reuptake Inhibitors Market in Asia Pacific

Selective serotonin reuptake inhibitors (SSRIs) elevate the extracellular level of neurotransmitters known as serotonin by inhibiting its uptake in presynaptic cells. Therefore, selective serotonin reuptake inhibitors are widely used as medication for the treatment of severe or persistent depression. In addition, selective serotonin reuptake inhibitors are also used in combination with therapies such as cognitive behavioral therapy (CBT).

Request a PDF Brochure with Report Analysis: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=13343

Furthermore, selective serotonin reuptake inhibitors are also used for mental conditions such as panic disorders, obsessive compulsive disorder (OCD), post-traumatic stress disorder (PTSD), severe phobias, including social phobia and agoraphobia, and generalized anxiety disorder (GAD). In addition, selective serotonin reuptake inhibitors are also used for the treatment of premenstrual syndrome, premature ejaculation, irritable bowel syndrome and fibromyalgia. Side effects of selective serotonin reuptake inhibitors include, low sex drive, dizziness, sickness, anxiety, erectile dysfunction in male population and blurred vision.

According to the World Health Organization (WHO), depression is the fourth leading cause of deaths and by 2020; it is expected to be the second leading cause of deaths worldwide. According to the National Institute of Mental Health (NIHM), part of National Institute of Health (NIH) of the U.S., in 2012, around 16 million adults above 18 years of age had at least one major depressive episode in the past year in the U.S. Risk of depression is twice in women population.

According to the Depression and Bipolar Support Alliance, the lifetime prevalence for female population is 20% to 26%. While life time prevalence of depression for male population is 8% to 12%. According to the article published by the British Psychology Society in June 2013, finding from the Office for National Statistics (ONS) states that approximately one fifth of the overall adult population experience depression. Thus, perpetually rising prevalence depression worldwide is the major factor driving the growth of the global selective serotonin reuptake inhibitors (SSRIs) market.

Geographically, the selective serotonin reuptake inhibitors market is segmented into North America, Europe, Asia Pacific and Rest of the World (RoW). Presently, Europe and North America are dominating the global selective serotonin reuptake inhibitors (SSRIs) market. Factors such as, divorce, unemployment, work pressure, and higher life expectations are resulting in higher rate of depression cases.

Furthermore, availability of advanced healthcare facilities and higher healthcare spending are driving the growth of selective serotonin reuptake inhibitors market in Europe and North America. Asia Pacific is a lucrative market for selective serotonin reuptake inhibitors (SSRIs). Factors such as rapidly growing prevalence of depression and mental conditions, rising awareness about depression and related treatments available and rising healthcare expenditure are expected to drive the selective serotonin reuptake inhibitors market in Asia Pacific region.

Though, prevalence rate of depression is high in Rest of the World (RoW), lack of awareness about related treatment is limiting the growth of the selective serotonin reuptake inhibitors market in this region. Brazil and Argentina are expected to show faster growth rate than other countries in Rest of the World owing to availability of well defined regulatory framework and developed healthcare infrastructure. African countries will experience slower growth rate in the forecast period due to poorly developed healthcare infrastructure coupled with lack of availability of regulatory framework.

Browse Full Research Report: http://www.transparencymarketresearch.com/selective-serotonin-reuptake-inhibitors-market.html

Some of the commercially available brands of SSRI include Fluvoxamine (Luvox), Citalopram (Celexa), Fluoxetine (Prozac), Paroxetine (Paxil), and Sertraline (Zoloft).

About Us

Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Contact Us

Transparency Market Research
State Tower,
90 State Street, Suite 700
Albany, NY 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com

This release was published on openPR.